Published in Rheumatology (Oxford) on January 22, 2009
Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One (2009) 2.00
Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res Ther (2012) 1.34
Cytokines in autoimmune uveitis. J Interferon Cytokine Res (2011) 1.19
Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis (2011) 1.10
Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci (2011) 1.00
Fms-like tyrosine kinase 3 ligand decreases T helper type 17 cells and suppressors of cytokine signaling proteins in the lung of house dust mite-sensitized and -challenged mice. Am J Respir Cell Mol Biol (2009) 0.96
The future of uveitis treatment. Ophthalmology (2013) 0.92
Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol (2013) 0.89
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol (2010) 0.88
Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome. Eye (Lond) (2014) 0.88
[Treatment of posterior noninfectious uveitis : Current situation and future developments]. Ophthalmologe (2016) 0.87
Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis. Am J Pathol (2010) 0.85
Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol (2014) 0.84
Emerging role of antioxidants in the protection of uveitis complications. Curr Med Chem (2011) 0.84
Small heat shock protein αA-crystallin prevents photoreceptor degeneration in experimental autoimmune uveitis. PLoS One (2012) 0.83
Ocular cytokinome is linked to clinical characteristics in ocular toxoplasmosis. Cytokine (2014) 0.81
IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye. J Immunol (2011) 0.81
Understanding autoimmunity in the eye: from animal models to novel therapies. Discov Med (2014) 0.81
Administration of Mycobacterium leprae rHsp65 aggravates experimental autoimmune uveitis in mice. PLoS One (2009) 0.81
Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. PLoS One (2013) 0.80
Expression of IL-8, IL-6 and IL-1β in tears as a main characteristic of the immune response in human microbial keratitis. Int J Mol Sci (2015) 0.78
Tocilizumab treatment for recalcitrant uveitic macular edema. Graefes Arch Clin Exp Ophthalmol (2012) 0.77
Upregulation of DR3 expression in CD4⁺ T cells promotes secretion of IL-17 in experimental autoimmune uveitis. Mol Vis (2011) 0.76
Suppression of interleukin-17-producing T-helper 17 cells by retinal pigment epithelial cells. Jpn J Ophthalmol (2011) 0.76
Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol (2015) 0.76
Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells. Br J Ophthalmol (2013) 0.76
Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate. Mol Vis (2014) 0.75
Systemic administration of an anti-tumor necrosis factor-alpha monoclonal antibody protects against endotoxin-induced uveitis in rats. Indian J Ophthalmol (2016) 0.75
Birdshot uveitis: current and emerging treatment options. Clin Ophthalmol (2013) 0.75
miR-23a, miR-146a and miR-301a confer predisposition to Vogt-Koyanagi-Harada syndrome but not to Behcet's disease. Sci Rep (2016) 0.75
CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection. J Leukoc Biol (2016) 0.75
Roles of interleukin-17 in uveitis. Indian J Ophthalmol (2016) 0.75
Expression Analysis of Cytokine and Chemokine Genes during the Natural Course of Murine Experimental Autoimmune Uveoretinitis. ISRN Inflamm (2012) 0.75
An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis. Curr Treatm Opt Rheumatol (2017) 0.75
Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody. Arthritis Res Ther (2017) 0.75
IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol (2017) 0.75
The Role of Th17 Cells in the Pathogenesis of Behcet's Disease. J Clin Med (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Interleukin-17 family members and inflammation. Immunity (2004) 16.16
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Foxp3 in control of the regulatory T cell lineage. Nat Immunol (2007) 5.94
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest (2006) 4.77
The IL-23/IL-17 axis in inflammation. J Clin Invest (2006) 4.32
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A (1993) 3.29
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol (2004) 3.28
IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev (2002) 2.99
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) (2007) 2.90
A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol (1988) 2.68
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 2.60
Th17 cells: a new fate for differentiating helper T cells. Immunol Res (2008) 2.45
Interleukin-17. Int Rev Immunol (1998) 2.31
Analysis of immunoregulatory cytokines in ocular fluid samples from patients with uveitis. Invest Ophthalmol Vis Sci (1998) 2.07
Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci (2000) 1.68
The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc (2007) 1.65
Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci (2005) 1.61
New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol (2007) 1.50
Biologics in the treatment of uveitis. Curr Opin Ophthalmol (2007) 1.44
Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol (1997) 1.43
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum (2008) 1.43
Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J Immunol (1996) 1.39
Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci (2007) 1.38
Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol (2007) 1.36
Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford) (2007) 1.33
Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. J Neurosci Res (2004) 1.31
Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev (2007) 1.28
Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett (2002) 1.25
Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci (2006) 1.22
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess (2007) 1.19
Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol (2007) 1.17
Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell Immunol (1997) 1.15
Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res (1992) 1.06
Endogenous posterior uveitis. Br J Ophthalmol (1990) 1.06
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther (2008) 1.04
Chemokine and chemokine receptor expression during experimental autoimmune uveoretinitis in mice. Graefes Arch Clin Exp Ophthalmol (2003) 1.04
The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther (2005) 1.02
Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm (2004) 0.99
Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur J Immunol (1997) 0.96
Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets (2007) 0.94
Infliximab therapy for pediatric Crohn's disease. Expert Opin Biol Ther (2007) 0.90
WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis. Int Immunol (2006) 0.90
Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol (2004) 0.86
Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis (2002) 0.86
TNF-alpha inhibitors in dermatology. Skin Therapy Lett (2007) 0.81
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol (2007) 12.76
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89
TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol (2007) 11.14
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89
Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med (2006) 7.76
Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature (2010) 7.50
Understanding the IL-23-IL-17 immune pathway. Trends Immunol (2005) 6.79
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity (2009) 6.05
Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol (2011) 5.98
IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med (2006) 5.76
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A (2006) 5.69
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity (2003) 5.60
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity (2006) 5.40
Th17 cell differentiation: the long and winding road. Immunity (2008) 5.40
In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med (2002) 5.28
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 5.10
Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol (2007) 4.90
IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev (2004) 4.78
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest (2006) 4.77
Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 4.57
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med (2012) 4.38
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol (2003) 4.25
Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med (2006) 4.18
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol (2007) 4.12
WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity (2003) 4.07
Distinct molecular mechanism for initiating TRAF6 signalling. Nature (2002) 3.82
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med (2005) 3.70
IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med (2007) 3.69
Suppressors of cytokine signaling and immunity. Nat Immunol (2003) 3.68
Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med (2004) 3.63
Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med (2006) 3.36
Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med (2009) 3.32
SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity (2002) 3.25
Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol (2003) 3.07
Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem (2008) 2.97
Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev (2004) 2.94
Single-molecule imaging analysis of Ras activation in living cells. Proc Natl Acad Sci U S A (2004) 2.84
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol (2004) 2.81
Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA (2009) 2.72
Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol (2003) 2.71
Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev (2002) 2.69
Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med (2008) 2.63
Medullary thymic epithelial cells expressing Aire represent a unique lineage derived from cells expressing claudin. Nat Immunol (2007) 2.61
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 2.60
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med (2006) 2.44
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med (2009) 2.41
IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol (2009) 2.39
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol (2004) 2.37
Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity (2003) 2.33
Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology (2006) 2.33
The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol (2005) 2.26
Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med (2002) 2.23
Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med (2005) 2.21
SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med (2003) 2.20
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest (2005) 2.20
Target cell defense prevents the development of diabetes after viral infection. Nat Immunol (2002) 2.18
Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med (2009) 2.17
Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina (2006) 2.14
The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol (2004) 2.09
Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro. Retina (2015) 2.03
Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One (2009) 2.00
Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol (2008) 1.98
Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab (2006) 1.96
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol (2005) 1.92
Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med (2012) 1.90
Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol (2002) 1.89
Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2. Immunity (2011) 1.87
Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J Immunol (2010) 1.86
The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol (2003) 1.84
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med (2006) 1.84
Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. J Exp Med (2011) 1.79
IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med (2006) 1.76
Egr-2 transcription factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated CD4+ T cells. Eur J Immunol (2013) 1.76
Membrane molecules mobile even after chemical fixation. Nat Methods (2010) 1.75